Loading clinical trials...

Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer | Clinical Trials | Clareo Health

COMPLETEDPhase 1NCT02947386

Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

This phase I/II trial studies the best dose and side effects of nimotuzumab when giving together with nivolumab and to see how well they work in treating patients with non-small cell lung cancer that ...

Lead sponsor: Roswell Park Cancer Institute•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Roswell Park Cancer Institute

PRIMARY OBJECTIVES: I. To determine the dose-limiting toxicities (DLT) and estimate the maximum tolerated dose (MTD) of nimotuzumab combined with nivolumab in the therapy of advanced non-small cell lung cancer (NSCLC) in order to establish the recommended phase II dose (RP2D). (Phase I) II. To evaluate the 12 month overall survival of nimotuzumab in combination with nivolumab in patients with advanced NSCLC. (Phase II) SECONDARY OBJECTIVES: I. Examine the safety and tolerability profile of nivolumab in combination with nimotuzumab in NCSLC . (Phase I) II. To evaluate the safety and the tolerability of nimotuzumab in combination with nivolumab using the Cancer Therapy Evaluation Program (CTEP) National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 4.0). (Phase I) III. Determine the immune analysis profile of nivolumab in combination with nimotuzumab. (Phase I) IV. Examine the efficacy of the study combination utilizing irRECIST guidelines. (Phase I) V. Overall response rate (ORR) per the immune-related Response Evaluation Criteria in Solid Tumors irRECIST. (Phase I) VI. Progression-free survival (PFS) rate at 1 year. (Phase I) VII. Progression-free survival (PFS). (Phase I) VIII. Overall survival (OS). (Phase I) IX. Disease control rate (DCR) and stable disease (SD). (Phase I) X. To evaluate the safety profile of Nimotuzaumab in combination with Nivolumab in NCSLC using the CTCAE V. 4. XI.To evaluate the efficacy of nimotuzumab in combination with nivolumab in patients with advanced NSCLC compared to historic outcomes of nivolumab alone, as determined by secondary measures of efficacy, including: overall response rate (ORR) per irRECIST. (Phase II) XII. To evaluate the efficacy of nimotuzumab in combination with nivolumab in patients with advanced NSCLC compared to historic outcomes of nivolumab alone, as determined by secondary measures of efficacy, including: progression-free survival (PFS) rate at 1 year. (Phase II) XIII. To evaluate the efficacy of nimotuzumab in combination with nivolumab in patients with advanced NSCLC compared to historic outcomes of nivolumab alone, as determined by secondary measures of efficacy, including: progression-free survival (PFS). (Phase II) XIV. To evaluate the efficacy of nimotuzumab in combination with nivolumab in patients with advanced NSCLC compared to historic outcomes of nivolumab alone, as determined by secondary measures of efficacy, including: overall survival (OS). (Phase II) XV. To evaluate the efficacy of nimotuzumab in combination with nivolumab in patients with advanced NSCLC compared to historic outcomes of nivolumab alone, as determined by secondary measures of efficacy, including: disease control rate (DCR) and stable disease (SD). (Phase II) TERTIARY OBJECTIVES: I. Examine the relationship of EGFR expression in tissue to PFS, OS, ORR and adverse events (AE). (Phase I) II. Examine the relationship of infiltrating CD4+ and CD8+ T cells and other immune and genetic markers, and their associated PD-1, CD45RA or CD45RO levels; PD-L1 expression within both neoplastic and non-neoplastic stromal elements of the tumor microenvironment to PFS, OS, ORR and AE. (Phase I) III. Comparison of response assessment criteria for a prospective analysis; irRECIST response assessment; irRC. (Phase I) IV. Examine the relationship of EGFR expression in tissue to PFS, OS, ORR and AE. (Phase II) V. Examine the relationship of infiltrating CD4+ and CD8+ T cells and other immune and genetic markers, and their associated PD-1, CD45RA or CD45RO levels. (Phase II) VI. Examine the relationship of PD-L1 expression within both neoplastic and non-neoplastic stromal elements of the tumor microenvironment to PFS, OS, ORR and AE. (Phase II) VII. Comparison of response assessment criteria for a prospective analysis; irRECIST response assessment; irRC. (Phase II) OUTLINE: This is a phase I, dose-escalation study of nimotuzumab followed by a phase II study. Patients receive nivolumab intravenously (IV) over 60 minutes and nimotuzumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days and then every 12 weeks.

Related studies

RECRUITINGPhase 2

Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT

NCT06222489 · Non-Small Cell Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer, and more

RECRUITINGPhase 1/2

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

NCT06071013 · Non-small Cell Lung Cancer, EGFR Gene Mutation, and more

RECRUITINGPhase 2

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

NCT06300424 · Non Small Cell Lung Cancer, EGFR Gene Mutation

RECRUITINGPhase 2

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

NCT05503667 · Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, and more

Active Not RecruitingPhase 1/2

Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer

NCT01629498 · Recurrent Lung Non-Small Cell Carcinoma, Stage II Non-Small Cell Lung Cancer AJCC v7, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 5, 2023Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment7

Start dateJun 2017

Last updatedOct 5, 2023

Condition

EGFR Gene Mutation Recurrent Non-Small Cell Lung Carcinoma Stage IIIA Non-Small Cell Lung Cancer Stage IIIB Non-Small Cell Lung Cancer Stage IV Non-Small Cell Lung Cancer

Locations shown

Roswell Park Cancer Institute

Buffalo, New York

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 5, 2023Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions